180 related articles for article (PubMed ID: 36171756)
21. Effect of Toxoplasma gondii infection on the junctional complex of retinal pigment epithelial cells.
Nogueira AR; Leve F; Morgado-Diaz J; Tedesco RC; Pereira MC
Parasitology; 2016 Apr; 143(5):568-75. PubMed ID: 26928468
[TBL] [Abstract][Full Text] [Related]
22. LBH589 Inhibits Glioblastoma Growth and Angiogenesis Through Suppression of HIF-1α Expression.
Yao ZG; Li WH; Hua F; Cheng HX; Zhao MQ; Sun XC; Qin YJ; Li JM
J Neuropathol Exp Neurol; 2017 Dec; 76(12):1000-1007. PubMed ID: 29136455
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-6-driven inflammatory response induces retinal pathology in a model of ocular toxoplasmosis reactivation.
Rochet É; Brunet J; Sabou M; Marcellin L; Bourcier T; Candolfi E; Pfaff AW
Infect Immun; 2015 May; 83(5):2109-17. PubMed ID: 25754200
[TBL] [Abstract][Full Text] [Related]
24. A potent HDAC inhibitor blocks Toxoplasma gondii tachyzoite growth and profoundly disrupts parasite gene expression.
Mouveaux T; Rotili D; Boissavy T; Roger E; Pierrot C; Mai A; Gissot M
Int J Antimicrob Agents; 2022 Mar; 59(3):106526. PubMed ID: 35041939
[TBL] [Abstract][Full Text] [Related]
25. The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
Vallo S; Mani J; Stastny M; Makarević J; Juengel E; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
Invest New Drugs; 2013 Apr; 31(2):265-72. PubMed ID: 22801803
[TBL] [Abstract][Full Text] [Related]
26. Clinical features and treatment of ocular toxoplasmosis.
Park YH; Nam HW
Korean J Parasitol; 2013 Aug; 51(4):393-9. PubMed ID: 24039281
[TBL] [Abstract][Full Text] [Related]
27. Toxoplasma gondii: acquired ocular toxoplasmosis in the murine model, protective role of TNF-alpha and IFN-gamma.
Gazzinelli RT; Brézin A; Li Q; Nussenblatt RB; Chan CC
Exp Parasitol; 1994 Mar; 78(2):217-29. PubMed ID: 8119376
[TBL] [Abstract][Full Text] [Related]
28. Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2.
Regel I; Merkl L; Friedrich T; Burgermeister E; Zimmermann W; Einwächter H; Herrmann K; Langer R; Röcken C; Hofheinz R; Schmid R; Ebert MP
Gastroenterology; 2012 Jul; 143(1):99-109.e10. PubMed ID: 22465428
[TBL] [Abstract][Full Text] [Related]
29. Synergistic Tumor Cytolysis by NK Cells in Combination With a Pan-HDAC Inhibitor, Panobinostat.
Afolabi LO; Bi J; Li X; Adeshakin AO; Adeshakin FO; Wu H; Yan D; Chen L; Wan X
Front Immunol; 2021; 12():701671. PubMed ID: 34531855
[TBL] [Abstract][Full Text] [Related]
30. Ocular Involvement Following an Epidemic of Toxoplasma gondii Infection in Santa Isabel do Ivaí, Brazil.
Silveira C; Muccioli C; Holland GN; Jones JL; Yu F; de Paulo A; Belfort R
Am J Ophthalmol; 2015 Jun; 159(6):1013-1021.e3. PubMed ID: 25743340
[TBL] [Abstract][Full Text] [Related]
31. New advances in immune mechanism and treatment during ocular toxoplasmosis.
Chen Z; Cheng S; Chen X; Zhang Z; Du Y
Front Immunol; 2024; 15():1403025. PubMed ID: 38799473
[TBL] [Abstract][Full Text] [Related]
32. HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells.
Song W; Tai YT; Tian Z; Hideshima T; Chauhan D; Nanjappa P; Exley MA; Anderson KC; Munshi NC
Leukemia; 2011 Jan; 25(1):161-8. PubMed ID: 21102427
[TBL] [Abstract][Full Text] [Related]
33. Neutrophil Activities in Human Ocular Toxoplasmosis: An In Vitro Study With Human Cells.
Ashander LM; Lie S; Ma Y; Rochet E; Washington JM; Furtado JM; Appukuttan B; Smith JR
Invest Ophthalmol Vis Sci; 2019 Nov; 60(14):4652-4660. PubMed ID: 31743940
[TBL] [Abstract][Full Text] [Related]
34. Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro.
Strobl JS; Cassell M; Mitchell SM; Reilly CM; Lindsay DS
J Parasitol; 2007 Jun; 93(3):694-700. PubMed ID: 17626366
[TBL] [Abstract][Full Text] [Related]
35. Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
Zang H; Qian G; Zong D; Fan S; Owonikoko TK; Ramalingam SS; Sun SY
Cancer; 2020 Jan; 126(9):2024-2033. PubMed ID: 31999837
[TBL] [Abstract][Full Text] [Related]
36. Detection of ocular Toxoplasma gondii infection in chronic irregular recurrent uveitis by PCR.
Lee SE; Hong SH; Lee SH; Jeong YI; Lim SJ; Kwon OW; Kim SH; You YS; Cho SH; Lee WJ
Korean J Parasitol; 2012 Sep; 50(3):229-31. PubMed ID: 22949751
[TBL] [Abstract][Full Text] [Related]
37. Atypical toxoplasmic retinochoroiditis.
Theodoropoulou S; Schmoll C; Templeton K; Dhillon B
BMJ Case Rep; 2012 May; 2012():. PubMed ID: 22669878
[TBL] [Abstract][Full Text] [Related]
38. The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression.
Chen S; Ye J; Kijima I; Evans D
Proc Natl Acad Sci U S A; 2010 Jun; 107(24):11032-7. PubMed ID: 20534486
[TBL] [Abstract][Full Text] [Related]
39. Indoleamine 2,3-Dioxygenase Activity During Acute Toxoplasmosis and the Suppressed T Cell Proliferation in Mice.
Ufermann CM; Domröse A; Babel T; Tersteegen A; Cengiz SC; Eller SK; Spekker-Bosker K; Sorg UR; Förster I; Däubener W
Front Cell Infect Microbiol; 2019; 9():184. PubMed ID: 31231617
[No Abstract] [Full Text] [Related]
40. Primary Acquired Toxoplasma Retinochoroiditis: Choroidal Neovascular Membrane as an Early Complication.
Mushtaq F; Ahmad A; Qambar F; Ahmad A; Zehra N
Cureus; 2019 Feb; 11(2):e4001. PubMed ID: 30989010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
